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Background: Cough remains the most common reason for patients to seek medical attention. We practised a
novel diagnostic algorithm for chronic and subacute cough.
Methods: Chronic and subacute cough patients with normal chest X-ray results and without respiratory tract
infections in the preceding eight weeks were recruited. The patients were divided into two groups: Group A,
patients with typical symptoms and signs of postnasal drip syndrome (PNDS), asthma syndromes (AS) and
gastroesophageal reflux disease (GERD); Group B, patients without the typical symptoms and signs. The two
groups received targeted or sequential empirical trials of therapy according to the algorithm.
Results: Among the 524 patients available for analysis in Groups A and B, 436 (83.6%) were diagnosed to have
PNDS (34.2%), AS (44.5%) and/or GERD (10.1%), among which 26 had two causes (6.0%) and 6 had three causes
(1.4%). After empirical trials of therapy, 81.5% of the patients were diagnosed. The mean time for diagnosis was
considerably shorter in Group A (13.1 ± 5.6 d) than in Group B (23.4 ± 7.2 d) (p < 0.01). The diagnosis rate of the
first trial in Group A (54.1%) was significantly higher than that in Group B (28.6%, p < 0.01).
Conclusions: The proposed algorithm is a promising and practical approach to diagnose chronic and subacute cough.
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Cough remains the most common reason for patients to
seek medical attention [1,2]. Chronic cough is a common
and frequently debilitating symptom that is often viewed
as an intractable problem [3]. Previous studies have
provided many recommendations on how to manage
chronic cough. They paid more attention to the objective
tests [4,5]. However, the problem is the low availability,
poor efficacy, and high cost of some major diagnostic tests
[6-12] in developing countries, such as in China. In
addition, in case of patients for whom a specific etiology
of chronic cough is not apparent, ACCP guideline said
empiric therapy for UACS in the form of a first-generation
A/D preparation should be prescribed before beginning
an extensive diagnostic workup [13]. Many studies have
suggested that gastroesophageal reflux disease (GERD)
be first treated empirically in patients with chronic
cough according to their typical symptoms and signs* Correspondence: chengzhenjincn@126.com
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unless otherwise stated.[14] or after ruling out postnasal drip syndrome (PNDS),
cough- variant asthma (CVA), and eosinophilic bronchitis
(EB) [3,11,15,16]. Therefore, current investigations must
be further refined, and more emphasis should be placed
on the diagnostic function of empirical trials of therapy
[9,10,16]. In this study, we set up a novel and practical
diagnostic algorithm and prospectively evaluated its
feasibility.Methods
Patient population
We consecutively studied immunocompetent patients
(age: 18 to 72 years) who were referred to our university
outpatient clinic between January 2005 and October
2011 for the evaluation of chronic cough (more than 8
weeks), and subacute cough (≥ 3 weeks but ≤ 8 weeks).
This study included patients with normal chest X-ray re-
sults and without a previous history of heart diseases and
respiratory tract infections in the preceding eight weeks,
bloody sputum, obvious long term or relapsing purulent
sputum and nasal and postnasal purulent discharge. ThisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of Helsinki and with approval of the Ethics Committee
of Harbin Medical University. Written informed
consent was obtained from all participants. The regis-
tration number of the prospective clinical trial is
ChiCTR-ONRC-10001130.
Diagnostic algorithm
The history of the patients was carefully reviewed, and
physical examination was performed. Patients with post-
infectious cough and heart diseases, as well as patients
with the highest cough score (frequency plus severity)
[11] of less than 3, were excluded. Patients who were
smokers or taking angiotensin-converting enzyme inhibi-
tors (ACEI) were identified. Patients with apparent puru-
lent sputum or purulent nasal or postnasal discharge or
bloody sputum were also excluded from this study. The
remaining patients were divided into two groups for em-
pirical trials of PNDS, asthma and/or GERD therapy, with
two weeks for one trial of therapy: Group A, patients with
typical symptoms or signs of PNDS, asthma syndrome
(AS) and/or GERD; Group B, patients with no typical
symptoms or signs. In Group A patients, the clinically
probable diseases were first treated according to the
typical symptoms or signs (if more than one probable
diseases they were treated simultaneously). Relevant
diseases were diagnosed when improvement was observed;
otherwise, the remaining disease was treated in the se-
quence of PNDS, AS and GERD. PNDS was first treated in
Group B patients. PNDS was diagnosed when improvement
was observed; otherwise, the remaining disease was treated
in the sequence of AS and GERD. Patients unresponsive to
all trials in Groups A and B underwent available tests, such
as parasinus or lung spiral CT (Toshiba Aquilion 64 CT,
Japan), spirometry (PROFILER DX.830501-206, USA) with
a bronchodilating test, bronchoscopy (Olympus BF 1 T180,
Japan) and gastroscopy (Olympus, Japan). Patients
continued to maintain daily cough diaries to evaluate
daily cough scores [11]. An improvement was defined
as increase in score (≥ 2) and improvement of cough by
50% or more. When these criteria are met, we diagnose
the relevant disease.
Typical symptoms, signs, and empirical trials of therapy
PNDS: Symptoms and signs: Nasal or postnasal discharge
(by history or physical examination), repetitive throat clear-
ing, a cobblestone appearance of the posterior pharyngeal
mucosa, nasal obstruction or congestion, facial pain,
frequent or repetitive sneezing, runny nose, itchy nose,
significant allergens and irritants.
Treatment: Avoidance of allergens and irritants; first-
generation antihistamines; decongestants [compound pseu-
doephedrine HCl sustained release capsules (SK&F, Tianjin,
China), one tablet, once or twice a day or chlorphenaminemaleate tablets, 4 mg, one to three times a day and pseu-
doephedrine hydrochloride tablets, 30 mg to 60 mg, three
times a day]; and topical intranasal corticosteroids (bude-
sonide nasalspray, 64 μg per nostril, twice a day) for two
weeks [for allergic rhinitis, second-generation antihista-
mines preferable, such as loratadine (Schering-Plough,
Shanghai, China), 10 mg, once daily].
Asthma Syndromes (AS) (including cough prominent
asthma, CVA and EB). Symptoms and signs: Seasonal
cough, history of asthma, significant atopy, wheezing,
tightness in the chest, shortness of breath, cough at night,
highly suspected allergens and irritants in the house,
working place and so on.
Treatment: Avoidance of allergens and irritants; short
acting β2 agonists, one puff to two puffs [terbutaline
inhaler (AstraZeneca, England), 0.25 mg to 0.5 mg or
albuterol inhaler (GlaxoSmithKline, England), 100 μg
to 200 μg], three to four times a day; inhaled corticosteroid
[budesonide (AstraZeneca, England), 400 μg, two times a
day] or fluticasone/salmeterol 50/250 (GlaxoSmithKline,
England), one puff, two times a day. After one week, if no
improvement was noticed, 30 mg/d to 40 mg/d of pred-
nisone was added for another week.
GERD: Symptoms and signs: Heartburn, regurgitation,
epigastric distension, dyspepsia, chest pain (ruling out
heart diseases), cough occurring after or during meal.
Treatment: Light meals three times a day; no food or
beverage between meals except for water. Do not eat or
drink 2 h to 3 h before lying down except for medications.
Elevate head of bed. Omeprasole (AstraZeneca, England),
40 mg, twice a day (morning and evening before meal),
and prokinetic agents three to four times a day, before
meals and bedtime [domperidone (Xian-Janssen Pharma-
ceutical Ltd., China) 40 mg/d to 80 mg/d], two weeks for
the treatment.
Statistical analysis
Data were expressed as mean ± standard deviation.
Student’s t test was used to compare quantitative data,
and chi-square test was used to compare qualitative data.
Statistical significance was set at p < 0.05. All reported
probability values were two-sided.
Results
A total of 700 qualified patients with chronic and subacute
cough were recruited for study. Among the 700 patients,
42 (6.0%) had smoker’s cough and 30 (4.3%) were taking
ACEIs. The remaining 628 patients were assigned to ei-
ther Group A (324 patients) or Group B (304 patients) for
empirical trials of therapy. In Groups A and B, 12.65%
(41/324) and 20.72% (63/304) of the patients, respectively,
were lost to follow up. Thus, 283 patients in Group A and
241 patients in Group B were available for further analysis.
There was no difference between the cough scores in
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Among these 524 patients, 199 were males (38.0%) and
325 (62.0%) were females. The median of age was 39 years
(between 18 and 72 years), and the median of cough
duration was 14 months (3 weeks to 12 years).
In Group A, 153 patients improved at the first trial of
therapy. Thus, the diagnosis rate of the first trial and the
mean positive predictive value of the typical symptoms
and signs were 54.1% (153/283). A total of 245 patients
were diagnosed; thus, the diagnosis rate was 86.6% (245/
283) in Group A. The mean time to diagnosis (MTD)
was 13.1 ± 5.6 days. In Group B, 69 patients improved at
the first trial of therapy. Thus, the diagnosis rate (28.6%,
69/241) in this group was significantly lower than in
Group A (p < 0.01). At the second trial of therapy, 84
patients improved. At the third trial of therapy, 29 patients
improved. The MTD was 23.4 ± 7.2 d, which was signifi-
cantly longer than that of Group A patients (p < 0.01). A
total of 182 patients showed improvement. Thus, the
diagnosis rate was 75.5% (182/241), that is not statistically
different from that of Group A (p > 0.05). 97 patients with
no improvement accepted available laboratory investiga-
tions. A total of 44 patients had positive results: 9 patients
had rhinosinusitis, 7 interstitial lung disease (2 pulmonary
alveolar proteinosis, 1 sarcoidosis, 2 hypersensitivity pneu-
monitis and others). In addition, 7 had bronchial tubercu-
losis, 4 relapsing polychondritis, 3 bronchial amyloidosis,
3 bronchial tumour, 2 chronic obstructive pulmonary dis-
ease, 2 lung neoplasm, 2 mediastinal disease, 2 bronchial
foreign body, 1 cardiac orifice polyp, 1 vocal cord polyp
and 1 bronchiectasis. A total of 53 patients had negative
results.
Among 524 patients who accepted empirical trials of
therapy and/or available laboratory investigations in
Groups A and B, 436 (83.6%) were diagnosed with PNDS
(179, including 9 patients diagnosed by CT (34.2%), AS
(233, 44.5%) and/or GERD (53, 10.1%). Among these
patients, 26 had two causes (26/436, 6.0%) and 6 patients
had three causes (6/436, 1.4%). A total of 35 patients
(35/524, 8.4%) were diagnosed as having other diseases,
and 53 patients (10.1%) were left undiagnosed. After
empirical trials of therapy, 81.5% of (427/524) patients
were diagnosed (Table 1 and Figure 1).
Discussion
PNDS, CVA, EB and GERD are the most common causes
of chronic cough [17]. Patients with subacute cough that
is not associated with an obvious respiratory infectionTable 1 The causes of chronic and subacute cough
PNDS AS GERD Others Undiagnosed
34.2% 44.5% 10.1% 8.4% 10.1%
AS, asthma syndromes; GERD, gastroesophageal reflux disease; PNDS;
postnasal drip syndrome. 26 patients with 2 causes, 6 patients with 3 causes.were evaluated in the same way as patients with chronic
cough [15]. Most cough patients with PNDS, CVA or EB
are responsive to targeted therapy in one week to two
weeks [17-20]. Cough patients with GERD improve in two
weeks with high-dose omeprazole therapy [11]. Currently,
many management strategies are available for cough;
however, balancing the cost with time to treatment
success is challenging [3]. Therefore, we designed a short-
term diagnostic algorithm for patients with chronic and
subacute cough; this algorithm focuses on empirical trials
of PNDS, asthma and GERD therapy [3,19,21]. We also
treated patients differentially. One group with suggestive
symptoms and/or signs was treated consequently, whereas
another group with no suggestive symptoms was treated
sequentially.
Among the patients included in this study, 6.0% were
smokers and 4.3% were taking ACEIs. Therefore, the
smoking history and relevant medications of patients
should be carefully reviewed. With this algorithm, we pre-
liminarily diagnosed 84.3% patients with PNDS (34.2%),
AS (51.1%) and/or GERD (10.1%) without employing 24 h
oesophageal pH monitoring (24 h OpHM), bronchial
provocation test (BPT) and induced sputum analysis (IS).
Approximately 5.4% of the patients were diagnosed to
have other diseases; only 10.1% patients were left undiag-
nosed (including 6 lost patients). Lai et al. [22] obtained
similar results in a prospective, multi-centre survey in
China, but we had more PNDS (34.1% vs 18.6%) and
GERD (10.1% vs 4.6%) patients, due to the cold weather in
Heilongjiang, the Northeastern province in China, com-
paring with the South warmer area in China.
Approximately, 81.5% of patients were diagnosed only
with the empirical trials of therapy within six weeks.
Even in Group B patients, who had no typical symptoms
and signs, 75.5% were diagnosed. Only 10.1% of the pa-
tients needed further investigations through 24 h OpHM,
BPT and IS. These results showed that the empirical trials
of therapy were crucial in diagnosing the causes of chronic
and subacute cough, whereas 24 h OpHM, BPT and IS
had limited clinical usefulness [23,24]. PNDS, AS and
GERD were the leading causes of chronic and subacute
cough aside from post-infectious cough. Therefore, we
should focus on these diseases when empirically treating
patients. In addition, delaying laboratory tests is desirable
for patients irresponsive to empirical trials of therapy [25].
The results of this study proved the proposed algorithm to
be practical because it reduced the number of investiga-
tions performed and minimised unnecessary delays in
treatment.
The mean positive predictive value of the typical
symptoms and signs was 54.1%, that is comparable with
the results of Ma [17] and Simpson [26] but considerably
lower than that of Kastelik [27]. In Groups A and B, the
diagnosis rates were 54.1% and 28.6% on the first trial,
Figure 1 Diagnostic algorithm. COPD, chronic obstructive pulmonary disease; CT, computed tomography; HP, hypersensitivity pneumonitis, ILD,
interstitial lung disease; PAP, pulmonary alveolar proteinosis.
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Group A (13.1 d) was significantly shorter than (23.4 d) in
Group B (p < 0.01). The targeted therapy to the patients
with suggestive symptoms and/or signs was better than
the sequential one. Therefore, familiarisation with the typ-
ical symptoms and signs, carefully reviewing the history
and performing physical examination are necessary for
targeted treatments [3,6]. These procedures promote the
improvement of many patients with empirical trials of
therapy in a shorter time.
Further follow up was not performed in patients who
showed improvement, which might underestimate multiple
causes. The patients should be followed up to confirm thediagnosis and/or add a new diagnosis with additional trials
and/or investigations when needed, which is beyond the
purpose of this study. Many patients in Group A were
treated for multiple causes simultaneously. Thus, we also
might overestimate multiple causes in Group A. We did
not differentiate between CVA and EB, which is needed for
the purpose of research. Although CVA and EB have some
differences, they have the same first line of therapy, i.e., cor-
ticosteroids. They also have a similar prognosis. However,
whether EB represents a distinct clinical entity or shares a
pathophysiological spectrum with CVA it remains to be
elucidated [3,18]. Clinically, diagnosing them as one syn-
drome is feasible and practical; this strategy is comparable
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pneumonia can be simply classified as steroid therapy-
sensitive and steroid therapy-insensitive groups. Moreover,
the primary objective for the patient is to eliminate the
most disruptive symptom as quickly as possible [29].
Many patients lacked compliance. Longer and/or more
expensive trials mean more patients lost to follow up.
Therefore, shortening the trials and educating the patients
are imperative [29]. This study suggests that treating AS
first [3] or AS and PNDS [30,31] simultaneously might be
an alternative approach to the diagnosis of patients with-
out typical symptoms or signs. However, further studies
must be conducted for verification.
Conclusions
In conclusion, PNDS, AS and GERD are the major causes
of chronic and subacute cough, except for post-infectious
cough. This novel algorithm, which pays more attention
to targeted or sequential empirical trials of therapy, re-
sulted in a high diagnosis rate. Delaying laboratory tests is
desirable for patients irresponsive to empirical trials of
therapy. In addition, the targeted therapy is significantly
better than the sequential therapy. Therefore, this algo-
rithm would be a promising and practical approach to the
diagnosis of chronic and subacute cough patients, espe-
cially in hospitals that lack some major diagnostic tests.
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